According to a recent study, more than 14% of the world’s population probably has, or has had, tick-borne Lyme disease – an infection that can cause long and debilitating symptoms. That number is set to rise too, as climate and environment changes continue to increase tick populations and distribution.
To help prevent some of these cases, pharmaceutical company Pfizer and biotech company Valneva will soon be testing a new vaccine against Lyme disease with 6,000 volunteers across Europe and in the US.
Read more at: https://www.theguardian.com/science/audio/2022/sep/08/could-a-new-vaccine-tackle-rising-rates-of-lyme-disease-podcast
